Clinical-stage biopharmaceutical company developing long-acting, once- or twice-yearly therapies for chronic diseases, particularly CNS conditions
Clinical-stage biopharmaceutical company developing long-acting, once- or twice-yearly therapies for chronic diseases, particularly CNS conditions. Its drug-delivery implant technologies are being developed for schizophrenia, opioid use disorder, bipolar disorder, spasticity, Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis.